Literature DB >> 6826327

Role of complement in murine corneal infection caused by Pseudomonas aeruginosa.

R P Cleveland, L D Hazlett, M A Leon, R S Berk.   

Abstract

The role of complement components C3 and C5 was examined in murine corneal infection induced by Pseudomonas aeruginosa. DBA/2 and Swiss-Webster mice are naturally resistant to experimental P. aeruginosa corneal infection. Mice of these two strains are able to restore a clear cornea within 4-6 weeks following Pseudomonas corneal challenge and are genetically deficient in the fifth component of complement. In contrast, ocular infection of congenic C5-deficient B10.D2o/Sn or normocomplementemic B10.D2n/Sn mice results in an identical pattern of susceptibility in which corneal perforation and phthisis bulbi occur. Taken together, these results indicate that C5 plays little or no role in susceptibility or resistance to Pseudomonas eye infection. In contrast, depletion of C3 in normally resistant DBA/2 mice using cobra venom factor (CoVF) diminishes the ability of these mice to restore a clear cornea following Pseudomonas infection. A single inoculation of CoVF, 24 hours prior to ocular challenge, is as effective in altering the response of DBA/2 mice as is continuous depletion of C3 during the course of infection using multiple inoculations of CoVF. Mice that are unable to clear Pseudomonas ocular infection following CoVF treatment regain this ability when the contralateral eye is infected after recovery of normal levels of C3. Depletion of C3 by CoVF treatment of DBA/2 mice, which had previously restored a clear cornea following Pseudomonas eye infection, again renders these mice susceptible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826327

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Immunology of the eye--1983.

Authors:  B J Mondino
Journal:  Surv Immunol Res       Date:  1984

2.  Effect of C3 depletion on experimental Pseudomonas aeruginosa ocular infection: histopathological analysis.

Authors:  L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

Review 3.  Molecular Mechanisms Involved in Pseudomonas aeruginosa Bacteremia.

Authors:  Stéphane Pont; Manon Janet-Maitre; Eric Faudry; François Cretin; Ina Attrée
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 4.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

5.  Kinetics of serum, tear, and corneal antibody responses in resistant and susceptible mice intracorneally infected with Pseudomonas aeruginosa.

Authors:  M J Preston; K A Kernacki; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Role of neutrophils, MyD88-mediated neutrophil recruitment, and complement in antibody-mediated defense against Pseudomonas aeruginosa keratitis.

Authors:  Tanweer S Zaidi; Tauqeer Zaidi; Gerald B Pier
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

7.  Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.

Authors:  R S Berk; I N Montgomery; L D Hazlett
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

Review 8.  Foundational concepts in the biology of bacterial keratitis.

Authors:  Lawson Ung; James Chodosh
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

Review 9.  The role of complement in ocular pathology.

Authors:  Nalini S Bora; Purushottam Jha; Puran S Bora
Journal:  Semin Immunopathol       Date:  2008-02-26       Impact factor: 9.623

10.  Activation of the lectin pathway of complement in experimental human keratitis with Pseudomonas aeruginosa.

Authors:  Michael Osthoff; Karl D Brown; David C M Kong; Mark Daniell; Damon P Eisen
Journal:  Mol Vis       Date:  2014-01-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.